Previous close | 30.52 |
Open | 30.84 |
Bid | 30.29 x 30000 |
Ask | 30.50 x 30000 |
Day's range | 30.84 - 30.84 |
52-week range | 24.08 - 36.25 |
Volume | |
Avg. volume | 4 |
Market cap | 4.185B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.03 |
Earnings date | 07 May 2024 |
Forward dividend & yield | 1.03 (3.38%) |
Ex-dividend date | 31 May 2024 |
1y target est | 51.00 |
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.